Israeli Oramed CEO to attend BIO CEO & Investor Conference in the US

News Desk

Oramed Pharmaceuticals Inc, a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems will participate in the upcoming BIO CEO & Investor Conference, taking place February 11-12, 2019 in New York City.

Mr. Nadav Kidron, Chief Executive Officer of Oramed, will present a corporate overview on February 12, 2019.

Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD™) technology is based on over 30 years of research by scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801).  The Company has completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).

A Conversation about Oral Insulin

Leave a Comment